Section Arrow
PYXS.NASDAQ
- Pyxis Oncology
Quotes are at least 15-min delayed:2026/04/03 09:27 EDT
Regular Hours
Last
 1.48
+0.01 (+0.68%)
Day High 
1.495 
Prev. Close
1.47 
1-M High
1.7 
Volume 
195.85K 
Bid
1.41
Ask
1.53
Day Low
1.4 
Open
1.43 
1-M Low
1.26 
Market Cap 
91.53M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.41 
20-SMA 1.47 
50-SMA 1.48 
52-W High 5.55 
52-W Low 0.8332 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.28/-1.33
Enterprise Value
108.51M
Balance Sheet
Book Value Per Share
0.85
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
13.86M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
COCPCocrystal Pharma1.51+0.49+48.04%-- 
BDRXBiodexa Pharmaceuticals plc0.8733+0.2593+42.23%-- 
IOBTIO Biotech0.0323-0.0114-26.09%-- 
GERNGeron Corp1.66------ 
ELABPmgc Holdings Inc5.72-8.28-59.14%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO,formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.